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Case report: lady with bone pains
for 5 years—parathyroid carcinoma
Azra Rizwan1*, Abid Jamal2, Maseeh Uzzaman3 and Saira Fatima4

Abstract
Background: Parathyroid cancer is a rare cause of primary hyperparathyroidism. It presents a diagnostic and therapeutic challenge that may not be recognized preoperatively, and is often not conclusively identified during the operation. We present the case of a lady with backache and hypercalcemia, but with inadequate work-up for her condition
for several years.
Case presentation: A middle aged lady of Asian descent presented with backache. Initial work up revealed mild
hypercalcemia, negative work up for multiple myeloma, negative sestamibi scan for parathyroid pathology. A phenomenally elevated parathormone (PTH) level—2105 pg/mL (16–87 pg/mL), and rising serum calcium, 15.1 mg/dL,
(8.6–10.5 mg/dL), ordered years later prompted a repeat sestamibi scan and ultrasonography of neck. Based on these
investigations, a diagnosis of primary hyperparathyroidism, with high suspicion of parathyroid cancer was made. The
patient underwent surgical tumour resection, with subsequent histopathological confirmation of diagnosis.
Conclusion: In the setting of hypercalcemia, PTH level assessment is a must. This helps to differentiate between the
parathyroid dependant and independent causes of high serum calcium, thereby encouraging a comprehensive pathway to the work up of the cause of hypercalcemia. The parathyroid cancer is a very rare cause of hypercalcemia, which
needs to be considered in the differentials of primary hyperparathyroidism, particularly in the setting of high PTH levels.
Keywords: Parathormone (PTH), Sestamibi scan, Hypercalcemia, Primary hyperparathyroidism, Case report
Background
Primary hyperparathyroidism affects approximately 1%
of the world’s adult population [1]. Single parathyroid
adenomas constitute the majority of cases (80–85%).
Most of the remaining cases are due to hyperplasia of
multiple parathyroid glands [1–3], with parathyroid cancer being a rare cause (1–2%) [1–3]. Parathyroid carcinoma presents a diagnostic and therapeutic challenge
as it is a rare endocrine malignancy, which may not be
recognized preoperatively, and often is not conclusively
identified during the operation [1].
Patients with parathyroid carcinoma usually present with a severe form of hyperparathyroidism at the
time of diagnosis including bone disease, renal disease, neurologic manifestations and gastrointestinal
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symptomatology, compared to the relatively asymptomatic presentation of benign parathyroid disease [1, 4].
However, diagnosis is sometimes made after routine
biochemical screening has revealed hypercalcemia in
an asymptomatic individual who is then found to have
raised PTH [1, 4, 5].
The etiology of parathyroid carcinoma is unclear,
although it has been associated with neck radiation in
sporadic cases [1]. Carcinomas have also been reported
in familial hyperparathyroidism, such as hereditary
hyperparathyroidism jaw tumor (HPT-JT) syndrome,
which carries an increased risk of parathyroid cancer
(15% vs 0.1% of sporadic parathyroid cancer) [6].
This case report describes a patient presenting with
nonspecific bone pains, whose initial workup showed
mild hypercalcemia, negative work up for multiple
myeloma and a negative sestamibi scan for parathyroid
pathology. A phenomenally elevated PTH level and rising serum calcium ordered years later prompted us to
request for a repeat sestamibi scan and ultrasonography
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of neck. Based on these levels & radiological tests, a diagnosis of primary hyperparathyroidism, with high suspicion of parathyroid cancer, was made. Following this, the
patient underwent surgical tumor resection, with subsequent histopathological confirmation of the diagnosis.

Case presentation
A 53 year old Pakistani lady presented to the Medicine
clinic of a local hospital in 2004 with a history of heel
pain and lower back pain for 5 months. In this period, the
patient had sustained a rib fracture and left humeral fracture. There was no history of diabetes, hypertension or
any other chronic disease. She had not been on any form
of medication, including steroids and traditional drugs
widely available and prescribed in the region, prior to the
onset of pain. At the time of the fractures, she had been
placed on non steroidal anti inflammatory agents, acetaminophen and tramadol. There was no history of illicit
drug use and she was a non smoker. Family history was
unremarkable, particularly in the context of bone disease,
and malignancy.
Initial laboratory investigations had shown a mildly elevated total calcium level of 10.8 mg/dL {2.7 mmol/L}-(no
albumin level result available from that time for correction). Parathormone levels (PTH) had not been determined. There was no vitamin d or renal function report
available from that time. X-Ray pelvis revealed lytic
lesions in the right iliac bone (Fig. 1). A magnetic resonance imaging (MRI) of the lumbosacral spine showed
some signal changes. The differentials based on the MRI
were metastatic bone disease or multiple myeloma.
Serum protein electrophoresis was normal. The patient
then got lost to follow-up. Her work up was resumed
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4 years later when her bone pains had started flaring up.
Bone marrow examinations done back in 2007, and later
in 2009, were negative for multiple myeloma. A bone
scan in November 2009 showed generalized increased
tracer uptake over the skull and both the axial and appendicular skeletons- findings in favor of metabolic bone
disease (Fig. 4a). An initial planar parathyroid sestamibi
scan requested by a general practitioner in November
2009 was negative for any functioning parathyroid adenoma in the neck or superior mediastinum. No serum
PTH report was available from this time either. Following
this workup, the patient was treated empirically for bone
pains with calcium supplements, an empiric vitamin d
injection, and intravenous zoledronic acid 5 mg (without
prior bone mineral density assessment via DXA scan).
This empiric treatment was instituted by an orthopedic surgeon whom she had been referred to. The patient
experienced only a slight improvement in bone pains
with this treatment and also developed nausea, vomiting and anorexia. Subsequently, she sought care at the
National Institute of Diabetes and Endocrinology, Dow
University Health Sciences, Karachi, Pakistan.
At presentation, the patient was well oriented and of
functional class 3 (wheel chair bound, able to walk only
with support). Her blood pressure was 110/70 mmHg.
Neck examination revealed no mass or lymphadenopathy. She had a significant proximal myopathy as
well as curved thighs. She had shortened fingers, and
spinal scoliosis was evident. Severe generalized bone
tenderness was elicited. There was no focal deficit.
Laboratory investigations at this time showed a calcium level of 15.1 mg/dL{3.775 mmol/L}, (corrected
for albumin of 3.6 mg/dL{36 g/L}); Vitamin D3 level of
33.92 ng/mL{84.664 nmol/L}; phosphorus 2.3 mg/dL
{0.743 mmol/L}and alkaline phosphatase of 1298 IU/L
{21.633 µkat/L}. Her 24 h urine calcium was 155 mg/
day {3.875 mmol/day}, with urine calcium to creatinine ratio of 0.02. Her creatinine level was 1.3 mg/dL
{114.92 µmol/L}(Table 1). The estimated glomerular

Table 1 Laboratory work up at presentation to Endocrine
Institute—5 years after onset of backache

Fig. 1 X-ray pelvis (punched out lytic lesions in right iliac bone)

Laboratory investigations

Normal ranges

Repeat corrected calcium 15.1 mg/dL

{8.6–10.5}

Phosphorus 2.3 mg/dL

{2.7–4.8}

Alkaline phosphatase 1298 IU/L

{29–132}

Parathormone 2105 pg/mL

{16–87}

25 OH vitamin D 33.92 ng/mL (following intramuscular
administration of vitamin D)

{> 30}

Serum Creatinine 1.3 mg/dL

{0.6–1.35}

24 h urine calcium 155 mg/day

{100–300}
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filtration rate (calculated through Cockcroft-Gault
equation) was 50 mL/min {0.835 mL/second).
Following these tests, the patient’s PTH level was
ordered and determined to be 2105 pg/mL {2105 ng/L}
[Table 1]. Ultrasonography of the neck showed a solid
hypo echoic, well-circumscribed mass lesion, measuring 1.8 × 1.2 cm at the lower pole of the right lobe of
thyroid. There were no calcifications or lymphadenopathy. Appearances were suggestive of parathyroid adenoma. Both lobes of the thyroid appeared normal. A
repeat planar sestamibi scan, (requested from a different institute in the city), revealed areas of tracer retention over upper and lower poles of the right lobe of
thyroid. The intensity of retained tracer was more over
the right inferior parathyroid gland. The findings were
highly suggestive of hyperparathyroidism (Fig. 2).
A bone mineral density scan showed a T score of
− 2.9 in the spine, − 3.8 in the hip and − 4.5 in the distal forearm, consistent with severe osteoporosis. The Z
scores at the spine, hip and distal forearm were − 2.0,
− 3.1 and − 3.6, respectively (Table 2).
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Table 2 Bone mineral density (BMD), T score and Z scores,
prior to and after parathyroidectomy
Scan date

BMD hip (g/cm2)◦
T score hip
Z score hip
BMD spine (g/cm2)◦
T score spine
Z score spine
BMD forearm (g/cm2)◦
T score forearm
Z score forearm

02/12/2009 (pre
operative)
0.498
− 3.6

− 3.1

0.729

− 2.9

11/01/2011
(post
operative)
0.886
− 0.5
0.2

0.933
− 1.0

− 2.0

− 0.0

− 4.5

− 3.2

0.333

− 3.6

0.402

− 2.2

◦BMD values at our institute (AKUH) for DXA done on 2.12.2009 were compared
with the study of 11.01.2011. The comparative analysis showed statistically
significant improvement in BMD values. The change in BMD was greater than
the Least Significant Change (LSC) of our Department at AKUH for each region
of interest. Therefore, it was considered significant (LSC for AKUH is: Hip: 0.030;
Spine: − 0.034; Forearm: 0.043)

As per Institute protocol and World Health Organization (WHO) guidelines BMD
of only the non-dominant hip (in this patient’s case, the right hip) was measured,
(position statement of International Society for Clinical Densitometry, attached
as Additional file 1)

Fig. 2 Parathyroid sestamibi scan (areas of tracer retention over upper and lower poles of right lobe thyroid-findings highly suggestive of primary
hyperparathyroidism)
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Ultrasonography of the kidneys revealed a single renal
stone (0.6 cm) and no neprocalcinosis.
Based on the biochemistry results of hypercalcemia,
associated with elevated PTH levels, a diagnosis of primary hyperparathyroidism was made. Subsequent sestamibi scan and neck imaging facilitated us to localize the
abnormal parathyroid gland. The DXA scan was useful
for evaluation of the bone mineral density. In view of the
phenomenally high levels of parathyroid hormone, (more
than 10 times upper limit of normal), the pre-operative
suspicion of parathyroid cancer was high [1, 7]. The
patient was rehydrated with intravenous fluids. Subcutaneous calcitonin injections at a dose of 4 units/kg every
12 h were administered to tide her over until the surgery.
Once her calcium levels had come down to 10.5 mg/dL
{2.625 nmol/L}L, she was operated upon. At surgery,
right hemithyroidectomy and inferior parathyroidectomy
with level six lymph node resection was done. The lymphadenectomy was performed as there was evidence of
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enlarged lymph nodes at neck exploration. The size of
the lesion was measured as 2.5 × 1.5 × 1 cm. Histopathology showed features consistent with parathyroid cancer
(Fig. 3a–d). Capsular invasion and focal vascular invasion
were noted. However, margins of excision were tumor
free. The excised lymph nodes did not show evidence
of tumour infiltration. The patient was not given external radiation therapy postoperatively. Literature review
revealed that post operative adjuvant radiation therapy
may only have a role in the management of patients with
a histologically positive margin following en bloc resection, or in those with lymph node metastases [1, 4, 8].
Postoperative PTH level, performed on the second day
of surgery, was 59 pg/mL {59 ng/L} (16–87). On the third
postoperative day, the patient’s serum corrected calcium
declined to 6 mg/dL {1.5 mmol/L}. This was associated
with paresthesias around her mouth and carpo-pedal
spasm. There were no seizures, although there was
some confusion in terms of time and place. Intravenous

Fig. 3 a (H&E, ×40): circumscribed parathyroid tumour composed of nests of polygonal cells with richly vascular stroma. b (H&E, ×100): tumour
cells infiltrating adjacent soft tissue. c (H&E, ×200): high power view of tumour showing polygonal cells exhibiting nuclear atypia and scattered
mitoses. d (H&E, ×400): tumour nests invading the blood vessel
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(See figure on next page.)
Fig. 4 a Bone Scan prior to parathyroidectomy (10/11/2009): generalized increased tracer uptake over the skull, both axial and appendicular
skeleton: findings in favour of metabolic bone disease. b Bone Scan 3 months after parathyroidectomy (18/02/2010): diffusely increased tracer
uptake in axial and appendicular skeleton with increased bone to soft tissue tracer uptake ratio-findings consistent with metabolic bone disease.
No appreciable change in scan pattern seen (from previous scan of 10/11/2009)

calcium (2 g calcium gluconate, equivalent to 180 mg
elemental calcium, in 50 mL 5% dextrose water) was
infused over 20 min. Re-monitoring of calcium levels
revealed persistent hypocalcemia. A slow infusion of calcium was initiated at an initial rate of 50 mL/h. This was
prepared by adding 100 mL of 10% calcium gluconate
(equivalent to 900 mg elemental calcium) to 1000 mL
5% dextrose water. The infusion rate was adjusted, with
a goal to maintain calcium levels at lower end of normal
range. On the fifth post-operative day, the calcium level
had risen to 9.0 mg/dL {2.25 nmol/L}. Neurologic examination was normal and she was tolerating oral diet. Oral
calcium supplementation was initiated (Qalsan D four
times daily-equivalent to 2 g elemental calcium per day).
She was discharged on oral calcium and vitamin D supplementation with active vitamin D, (calcitriol) 0.25 µg
twice daily, in a stable condition.
At follow-up, her appetite and mobility had improved
significantly, although she continued to experience bone
pains. Corrected calcium was 9.5 mg/dL {2.375 nmol/L}.
A repeat skeletal scintigraphy done 3 months after parathyroidectomy did not demonstrate a significant change
in the lytic lesions (Fig. 4a, b). A repeat DXA scan 2 years
down the line revealed a significant improvement in bone
mineral density at all sites, though more so at the spine
and hip, than at the forearm (Table 2). Thereafter, we followed her clinically, as she was not keen to have further
radiologic testing done. We have been monitoring her
calcium and PTH levels on an annual basis. They have
remained within their normal range till date (2018). She
is now functional class 2, (no longer wheel chair bound),
and on regular calcium and vitamin D supplements
(patient perspective, attached as Additional file 2).

Discussion and conclusion
This case highlights several unusual features of a very
rare disease of the parathyroid gland—parathyroid cancer—documented to be a causative factor in less than
1% of cases of hyperparathyroidism [1–3]. Compared
with patients with parathyroid adenomas, patients with
parathyroid carcinomas are more likely to have symptoms, a neck mass, bone and kidney disease, marked
hypercalcemia, very high serum parathyroid hormone
(PTH) concentrations and, subsequently, high urinary
calcium losses [1, 7]. In this patient, although the preoperative parathyroid hormone level was inexorably high
at 2105 pg/mL (16–87), the 24 h urine calcium was not

as high (155 mg/day) as expected in association with
these levels of PTH [9–11], given a reasonably sufficient
(840 mL) 24 h urine collection. The relatively low 24 h
urine calcium could in part be explained by the reduction
of renal function (creatinine clearance of 50 mL/min).
The serum calcium levels were not as high as reported
in the literature for parathyroid cancers [1, 7, 9]. The initial level was 10.8 mg/dL {2.7 mmol/L}. The highest level
documented was 15.1 mg/dL{3.775 mmol/L}, that too
only after she had been placed on calcium and vitamin
d supplementation by an orthopedic surgeon, whom she
had presented to for her bone pains. The orthopedic surgeon had probably been treating her as a regular case of
primary osteoporosis, without a complete evaluation and
consideration for the initial mildly elevated calcium of
10.8 mg/dL {2.7 mmol/L}. The possibility exists that her
baseline vitamin D level, unfortunately not assessed prior
to institution of parental vitamin d, may have been low.
This may have led to the relatively lower baseline levels
of calcium than expected in the context of parathyroid
carcinoma. Unmasking of primary hyperparathyroidism
subsequent to vitamin D replacement has been reported
in the literature [10].
Ultrasonography of our patient revealed a 1.8 × 1.2 cm
hypo echoic, though well-circumscribed solid lesion,
with no calcifications or lymphadenopathy, at lower
pole of the right lobe of the thyroid. Cetani et al. in their
review state that mass size > 3 cm, marked hypoechogenicity, a lobulated non homogenous pattern, calcifications and degenerative changes may raise the suspicion
of parathyroid cancer [1, 12]. Another unusual feature
of this patient’s presentation was that the first sestamibi
scan was negative. The repeat scan (Fig. 2) (requested
from a different radiologic centre) showed some tracer
retention over the upper and lower poles of right lobe
of thyroid, which co related with findings obtained on
ultrasonography. The latter had revealed a mass lesion at
the lower pole of the right lobe of the thyroid, though no
malignant characteristics, such as calcifications, degenerative changes or irregular halo sign [1, 12] had been
reported. Although both scans were planar, the negative scan had been done using a low energy general purpose collimator (LEGP), while the repeat scan was done
using a low-energy high resolution collimator (LEHR).
The discrepancy between the results of the two sestamibi scans could have been due to these different techniques employed. Sestamibi scan does not distinguish
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a parathyroid adenoma from a parathyroid carcinoma
[11]. Considering the phenomenally raised parathormone levels, however, a hot nodule had been anticipated.
The majority of cases of parathyroid cancer reported
in the literature have described a dramatic lighting up
of the lesion on the sestamibi scan, with a sensitivity of
85–100%, and specificity of 100% [13]. In our case, there
was subtle tracer retention over upper and lower poles of
right lobe of thyroid, with intensity of retention higher
over the inferior pole. A pin- hole collimator technique
to obtain a magnified, higher resolution image focused
on the neck, was not available at either Institute at that
time. There has been a case reported in the literature of
false negative scintigraphy in parathyroid carcinoma with
associated brown tumours (term discussed below) [13].
From the neurologic and renal stand point the patient
had been well preserved. There had been no manifestations of altered sensorium, even at the stage when
her serum calcium had reached a level of 15.1 mg/dL
{3.775 mmol/L}. Ultrasonography of her kidneys had
revealed normal sized kidneys with intact corticomedullary differentiation, no nephrocalcinosis and a single
small renal stone. In most cases of parathyroid carcinoma, central nervous system and renal manifestations
are apparent at the time of diagnosis [1, 4]. In the case of
this patient, the disease, though remaining undiagnosed
for 5 years, seems to have involved predominantly the
skeletal system, leading to severe osteoporosis. Her shortened fingers on physical examination were indicative of
pharyngeal tuft resorption. The low Z scores of ≤− 2.0
at the spine, hip and forearm were highly suggestive of a
secondary cause of osteoporosis. The bone mineral density at the forearm (T score − 4.5) was lower than at the
spine (T score − 2.9) Table 2. This is in keeping with the
fact that the parathormone has a greater impact on cortical bone (distal forearm and hip) than the spine, which
consists of cancellous bone [12]. Correspondingly, a follow up dexa scan 2 years after the parathyroidectomy
revealed a significant improvement in bone mineral density at all the sites, though a slower improvement was
observed at the forearm (Table 2). This was likely related
to the prolonged preoperative exposure to high levels
of parathormone at the cortical bones of the forearm.
The lytic lesions of the bones in primary hyperparathyroidism result from excess osteoclast activity leading to
a collection of osteoclasts intertwined with fibrous tissue and undermineralized woven bone. Haemosiderin
accumulation gives rise to the brown disclouration—
hence originated the label of “brown tumours” for these
lytic lesions [2, 12]. Correspondingly, as evident in this
lady’s case, these lesions were originally interpreted as
metastases or myeloma lesions radiologically. Both these
conditions, though important differentials to consider,
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result in PTH-independent hypercalcemia, versus the
PTH- dependant hypercalcemia ensuing from primary
hyperparathyroidism.
Long-standing hypercalcemia resulting from autonomous parathormone production leads to suppression of
the remaining parathyroid glands. Following parathyroidectomy, recovery of function has been variable, ranging
from hours to a couple of weeks. In many cases, oral calcium supplementation alone adequately restores calcium
levels. In some situations, as was the case in our patient,
more severe hypocalcemia ensues, requiring intravenous calcium supplementation. As a result of PTH suppression, the 1-alfa hydroxylation of vitamin D, at the
renal tubular level, is concurrently reduced. This necessitates supplementation with the active form of vitamin
d. This condition has been described as the “hungry bone
syndrome”, usually found to occur 3–5 days following
parathyroidectomy. The reason for its development is
thought to be due to significant increases in osteoblastic
function, bone formation and deposition of calcium and
phosphorus in previously deprived bones [2, 14, 15]. Our
patient had a long-standing history of primary hyperparathyroidism, phenomenally elevated PTH levels, marked
hypercalcemia and elevated alkaline phosphatase levels
(indicating high bone resorption). She also had radiologic
signs of osteitis fibrosa cystica (Fig. 1). These hallmarks
very likely led to development of the typical hungry
bone syndrome in this case. Concomitant with her longstanding history of hyperparathyroidism, the lytic lesions
on her follow-up bone scintigraphy, done 3 months following parathyroidectomy, did not show any significant
improvement.
A number of important lessons can be learned from
this case. In the setting of bone pains and hypercalcemia, the parathormone level, along with a vitamin D
assessment and renal function tests, should have been
checked when the patient had first presented to the
general practitioner back in 2004. This would have differentiated between parathyroid-dependant and parathyroid-independent hypercalcemia, and may have
avoided an exhaustive work up for multiple myeloma.
The patient had previously undergone bone marrow
examinations on two occasions, both showing a normal result. The physicians may have been misguided
by the only two differentials suggested on the MRI
Lumbosacral spine report: “Multiple Myeloma versus
metastasis.” In both these conditions, parathyroid levels
are suppressed in the setting of hypercalcemia. Unfortunately, the parathormone level and relevant testing,
including vitamin D and renal function tests, were only
requested 5 years down the line when the patient first
presented to the Endocrinologist. This led to an unacceptable delay in the diagnosis. It is unclear why the

Rizwan et al. BMC Res Notes (2018) 11:617

first sestamibi scan was requested, without a prior parathyroid hormone level assessment, at the time when the
patient was following up elsewhere for her condition.
In the setting of hypercalcemia, parathyroid hormone
level assessment is a must, to differentiate between the
parathyroid dependant and independent causes of high
serum calcium, thereby encouraging a comprehensive
pathway to the work-up of the cause of the hypercalcemia. The Parathyroid carcinoma is a very rare cause
of hypercalcemia that can present in several ways and
which needs to be considered in the differentials of primary hyperparathyroidism, particularly in the setting
of high parathyroid hormone levels.
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